Curated News
By: NewsRamp Editorial Staff
October 07, 2026
VERAXA Biotech Advances FDA-Aligned Methods to Reduce Animal Testing
TLDR
- VERAXA Biotech uses FDA-aligned NAMs to accelerate clinical advancement and cut costs, giving it a competitive edge in antibody-based cancer therapies.
- VERAXA's NAMs panel evaluates BiTAC-based T cell engagers and antibody-drug conjugates using ex vivo patient-derived xenograft models, reducing animal use and preclinical cycle time.
- VERAXA Biotech's NAM strategy significantly reduces animal testing in cancer research, making tomorrow better by advancing more ethical and efficient drug development.
- VERAXA Biotech's lead candidates were tested on 10 patient-derived xenograft models using only about 10 mice, compared to over 200 for typical in vivo studies.
Impact - Why it Matters
This development signals a significant shift in preclinical cancer research, where innovative NAMs can dramatically reduce animal testing while maintaining clinical relevance. By cutting the number of mice needed from over 200 to just 10 in certain studies, VERAXA not only addresses ethical concerns but also potentially speeds up drug development and lowers costs. If widely adopted, such approaches could streamline the path to clinical trials, bringing new cancer therapies to patients faster. Moreover, the validation of VERAXA's BiTAC platform through these methods reinforces the potential of bispecific T cell engagers and antibody-drug conjugates in treating solid tumors, offering hope for more effective and targeted treatments.
Summary
VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced a strategic update on its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. According to the company, this approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing. VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. The company’s lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required only about 10 mice in total, compared to an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC® is a registered trademark of VERAXA Biotech GmbH. For more information, visit the full press release at https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. This news was originally distributed by NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, VERAXA Biotech Advances FDA-Aligned Methods to Reduce Animal Testing
